India Requires The Suspension Of Chinese-Made Kits

“Our company has always insisted on product quality first, and our product quality meets the quality standards of China and exporting countries. We are fully confident in this.” Wondfo Bio said in the statement.
Guangzhou Fondfo Biotechnology Co., Ltd. issued a statement on the 28th and was “very regretful” to the decision of the Indian Medical Research Council (ICMR) to stop using the company ’s new coronavirus rapid antibody test kit, saying it is confident in the quality of its products. The Indian Medical Research Council’s above comments, the company is actively communicating.
According to the “Hindustan Times” local time report on the 27th, the Indian Medical Research Council (ICMR) in its revised guide for the use of rapid antibody detection kits recommended that states stop using Guangzhou Wondfo Biotechnology Co., Ltd. and Zhuhai Li Kits provided by Bead Reagent Co., Ltd. ICMR stated that they evaluated the test kits from Wondfo and Livzon and found that “despite the good performance in early detection”, there was a “significant difference” in their sensitivity and requested that these test kits be returned to the suppliers. .
“Our company was informed of the opinion of the Indian Medical Research Council (ICMR) on ‘recommendation to stop using new coronavirus rapid antibody detection reagents provided by our company and another supplier’, and we express our regret for this.” On the 28th In the statement issued, Wondfo said on the biological side.
According to the statement, Wondfo Bio-New Coronavirus Antibody Test Reagent (Colloidal Gold Method) is one of the first batch of test reagents to obtain an Indian import license, and has passed the Indian National Virus in Pune, a subsidiary of the Indian Medical Research Council Research Institute (NIV) verification and approval. “Our company has always insisted on product quality first, and our product quality meets the quality standards of China and exporting countries. We are fully confident in this.” Wondfo Bio said in the statement.
On the 28th, Counsellor Ji Rong, spokesperson of the Chinese Embassy in India, mentioned in the reporter’s question that the storage, transportation, and use of the New Crown Antibody Test Reagents have strict requirements. Lead to deviations in detection accuracy. The Indian Medical Research Council also clearly pointed out that the rapid test reagents are only used to monitor the epidemic situation, and cannot be used to determine the diagnosis of cases, and cannot replace nucleic acid testing. States should strictly abide by the method and purpose of use.
Wondfo Bio revealed that the company is actively communicating the above opinions of the Indian Medical Research Council. The statement also stated that Wondfo Bio has always and will continue to keep information transparent and promptly disclose a series of measures taken to ensure the supply and quality of testing reagent products to ensure that its products can meet the urgent needs of countries when the global response to COVID-19